Session 113 - 12th CROI

Home

Session 113 Poster Abstracts
Pharmacology of Protease Inhibitors
Wednesday, 1:30 - 3:30 pm
Hall A

654	Population Pharmacokinetic Assessment of Systemic Steady-state Tipranavir Concentrations for Adults Administered Tipranavir/Ritonavir 500/200 mg Twice Daily Chan-Loi Yong*¹, J Sabo¹, C Oksala¹, T MacGregor¹, V Kohlbrenner¹, S McCallister¹, J Leith², and D Mayers¹ ¹Boehringer Ingelheim Pharma Inc, Ridgefield, CT, USA and ²Boehringer Ingelheim GmbH, Ingelheim, Germany
655	Pharmacokinetics of Once-daily Saquinavir Hard-gel Capsule with Low-dose Ritonavir or Full-dose Atazanavir in Seronegative Volunteers: ASPIRE I Stephen Becker*¹, M Tse¹, F Sterman¹, T Kakuda², and E Acosta³ ¹Pacific Horizon Med Group, San Francisco, CA, USA; ²Roche, Nutley, NJ, USA; and ³Univ of Alabama at Birmingham, USA
656	The Clinical Correlations of Trough Plasma Atazanavir Levels in a Cohort of HIV-1-positive Individuals Receiving HAART Alan Winston*¹, M Bloch², A Carr³, J Amin¹, P Mallon¹, J Ray³, D Marriott³, D Cooper¹, and S Emery¹ ¹Natl Ctr in HIV Epidemiology and Clin Res, Univ of New South Wales, Sydney, Australia; ²Holdsworth House Gen Practice, Sydney, Australia; and ³St Vincent's Hosp, Sydney, Australia
657	Effect of Rifampin on Steady--state Pharmacokinetics of Atazanavir and Ritonavir in Healthy Subjects D Burger¹, S Agarwala², M Child*², Y Wang², and D Grasela² ¹Univ Med Ctr Nijmegen, The Netherlands and ²Bristol-Myers Squibb, Princeton, NJ, USA
658	Pharmacokinetic Effect of Omeprazole on Atazanavir Co-administered with Ritonavir in Healthy Subjects Sangeeta Agarwala*, K Gray, Y Wang, and D Grasela Bristol-Myers Squibb, Princeton, NJ, USA
659	Neither MDR1 Genotypes (C3435T, G2677T/A, C1236T) nor Hepatic and Intestinal CYP 3A4 Activity Are Associated with Plasma and Intracellular Concentrations of Lopinavir and Ritonavir Christoph Wyen*¹, A Jetter¹, R Aarnoutse², J Ford³, T Klaassen¹, A Lazar¹, F Abdulrazik¹, N Schmeißer¹, E Schömig¹, D Back³, D Burger², U Fuhr¹, and G Fätkenheuer¹ ¹Univ of Cologne, Germany; ²Univ of Nijmegen, The Netherlands; and ³Univ of Liverpool, UK
660	Lopinavir/Ritonavir Parameters of Systemic Exposure in HIV-infected Children following Twice- or Once-daily Administration Raffaella Rosso*¹, A Di Biagio¹, C Dentone¹, M Bassetti¹, A Ferrazin¹, G Castelli Gattinara², A Viganò³, M Merlo³, C Giaquinto⁴, O Rampon⁴, and D Bassetti¹ ¹Univ of Genoa, Italy; ²Hosp Bambino Gesù, Rome, Italy; ³Hosp Luigi Sacco, Milan, Italy; and ⁴Univ of Padua, Italy
661	Does Nelfinavir Induce Lactose Intolerance? Adriana Andrade*, C Cuffari, C Sears, and C Flexner Johns Hopkins Univ, Baltimore, MD, USA
662	Management of Drug-to-drug Interactions between Tacrolimus and HiAART Elina Teicher*¹, A M Taburet², I Vincent², L Faivre³, C Abbara¹, D Samuel¹, J C Duclos-Vallée¹, and D Vittecoq¹ ¹Hosp Paul Borusse, Villejuif, France; ²Hôpital Kremlin Bicêtre, Villejuif, France; and ³Hosp Paul Borusse, Villejuif, France